Osteomyelitis: Diagnosis and Treatment

David C. Bury, DO, MPH
Tyler S. Rogers, MD
Michael M. Dickman, DO, MBA

American Family Physician. 2021;104(4):395-402.

Author disclosure: No relevant financial affiliations.

Patient information: See related handout on osteomyelitis, written by the authors of this article.

Osteomyelitis is an inflammatory condition of bone secondary to an infectious process. Osteomyelitis is usually clinically diagnosed with support from imaging and laboratory findings. Bone biopsy and microbial cultures offer definitive diagnosis. Plain film radiography should be performed as initial imaging, but sensitivity is low in the early stages of disease. Magnetic resonance imaging with and without contrast media has a higher sensitivity for identifying areas of bone necrosis in later stages. Staging based on major and minor risk factors can help stratify patients for surgical treatment. Antibiotics are the primary treatment option and should be tailored based on culture results and individual patient factors. Surgical bony debridement is often needed, and further surgical intervention may be warranted in high-risk patients or those with extensive disease. Diabetes mellitus and cardiovascular disease increase the overall risk of acute and chronic osteomyelitis.

Osteomyelitis is an inflammatory condition of bone secondary to infection; it may be acute or chronic. Symptoms of acute osteomyelitis include pain, fever, and edema of the affected site, and patients typically present without bone necrosis in days to weeks following initial infection. Chronic osteomyelitis develops after months to years of persistent infection and may be characterized by the presence of necrotic bone and fistulous tracts from skin to bone.1,2 Osteomyelitis is further classified by mechanism of infection as hematogenous or nonhematogenous. With hematogenous osteomyelitis, bacteria are seeded into bone secondary to a bloodstream infection and the condition is most common in children, older adults, and immunocompromised populations.13 Nonhematogenous osteomyelitis occurs from direct inoculation in the setting of surgery or trauma or with spread from contiguous soft tissue and joint infections.1,2

SORT: KEY RECOMMENDATIONS FOR PRACTICE

A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to https://www.aafp.org/afpsort.

BEST PRACTICES IN INFECTIOUS DISEASE

Recommendations from the Choosing Wisely Campaign
RecommendationSponsoring organization
Do not routinely use magnetic resonance imaging to diagnose bone infection (osteomyelitis) in the foot.American Podiatric Medical Association

Source: For more information on the Choosing Wisely Campaign, see https://www.choosingwisely.org. For supporting citations and to search Choosing Wisely recommendations relevant to primary care, see https://www.aafp.org/afp/recommendations/search.htm.

Etiology

Methicillin-sensitive Staphylococcus aureus is the most frequently identified pathogen across all types of osteomyelitis, followed by Pseudomonas aeruginosa and methicillin-resistant S. aureus. Hematogenous osteomyelitis is often monomicrobial and can occur from aerobic gram-negative rods or from P. aeruginosa or Serratia marcescens in injection drug users.4 Vertebral osteomyelitis is the most common type of hematogenous osteomyelitis and is polymicrobial in 5% to 10% of cases.1 Blood cultures may be negative if osteomyelitis develops following bacterial clearance from the bloodstream. Nonhematogenous osteomyelitis can be polymicrobial; S. aureus is the most common pathogen in addition to coagulase-negative staphylococci and gram-negative aerobes and anaerobes. Polymicrobial diabetic foot infections and decubitus ulcers may include Streptococcus species and Enterococcus species.1 Less common pathogens can be associated with certain clinical conditions, including immunocompromise (Aspergillus species, Mycobacterium tuberculosis, Candida species), sickle cell disease (Salmonella species), HIV infection (Bartonella henselae), and tuberculosis (M. tuberculosis).1,5,6

Clinical Features

The clinical presentation of nonhematogenous osteomyelitis varies and symptoms are often non-specific. Signs and symptoms common to all sub-types may include pain, edema, and erythema. Acute osteomyelitis may present with a more rapid onset of symptoms (development over days) and is more likely to be associated with fever. Systemic symptoms are not common in chronic osteomyelitis, and the presence of fistulous tracts from skin to bone is diagnostic. Long-standing, nonhealing ulcers and nonhealing fractures may also be associated with chronic osteomyelitis.

Patients with diabetic neuropathy are at higher risk of developing osteomyelitis secondary to local spread from diabetic foot infections and unrecognized wounds.2 Smoking increases the risk of osteomyelitis from diabetic foot infections and healing fractures.7 Peripheral vascular disease and poorly healing wounds (e.g., decubitus ulcers) are more likely to lead to bone inflammation. Osteomyelitis secondary to diabetic foot ulcers can be difficult to diagnose given chronic changes from vascular insufficiency and ischemia.8

Hematogenous osteomyelitis often presents similarly to nonhematogenous disease. The most common form of hematogenous osteomyelitis is vertebral; patients often have back or neck pain and muscle tenderness, sometimes followed by fever. Hematogenous osteomyelitis may also occur in the sternoclavicular, pelvic, and long bones.9 When hematogenous osteomyelitis affects prepubertal children, it typically occurs in the metaphysis of long bones adjacent to growth plates, with a predilection for the tibia and femur.1

Diagnosis

A diagnosis of osteomyelitis should be considered in any patient with acute onset or progressive worsening of musculoskeletal pain accompanied by constitutional symptoms such as fever, malaise, lethargy, and irritability. Constitutional symptoms do not always occur in adults, especially in the setting of immunocompromise. The index of suspicion for osteomyelitis should be higher in patients with underlying conditions, including poorly controlled diabetes mellitus, neuropathy, peripheral vascular disease, chronic or ulcerated wounds, history of recent trauma, sickle cell disease, history of implanted orthopedic hardware, or a history or suspicion of intravenous drug use. A dedicated physical examination can increase the likelihood of diagnosing osteomyelitis if findings include erythema, soft tissue infection, bony tenderness, joint effusion, decreased range of motion, or exposed bone. The probe-to-bone test may be useful to rule out diabetic foot osteomyelitis in low-risk patients.10,11

The differential diagnosis of osteomyelitis includes soft tissue infection, gout, Charcot arthropathy, fracture, malignancy, bursitis, osteonecrosis, sickle cell vasoocclusive pain crisis, and SAPHO syndrome (synovitis, acne, pustulosis, hyperostosis, and osteitis). Uncertain clinical diagnosis should prompt further workup that includes laboratory evaluation and imaging (Table 12,9,12,13 ). Definitive diagnosis is made with a positive culture from biopsy of the affected bony structure. Polymerase chain reaction testing may help in the rapid diagnosis of organisms or for cultures taken after antibiotic therapy.12,14 Bone biopsy remains the diagnostic standard but is not always feasible. Some evidence suggests that biopsy should be reserved only for select cases because the results may not lead to treatment alterations.15

TABLE 1. Clinical Findings Suggesting Osteomyelitis

Imaging studies (e.g., plain film radiography, magnetic resonance imaging, bone scintigraphy) demonstrating contiguous soft tissue infection or bony destruction
Clinical signs
Chronic wound overlying surgical hardware
Chronic wound overlying traumatic injury or fracture
Exposed bone
Persistent sinus tract
Tissue necrosis overlying bone
Laboratory evaluation
Elevated C-reactive protein level
Elevated erythrocyte sedimentation rate
Leukocytosis
Positive blood cultures
Thrombocytosis

Note: If osteomyelitis is suspected, a bone biopsy with bacterial culture should be considered for definitive diagnosis.

Adapted with permission from Hatzenbuehler J, Pulling TJ. Diagnosis and management of osteomyelitis. Am Fam Physician. 2011;84(9):1028, with additional information from references 9, 12, and 13.

LABORATORY EVALUATION

Initial laboratory evaluation should include a complete blood count, erythrocyte sedimentation rate, C-reactive protein, and blood cultures. Leukocytosis may be present in acute osteomyelitis, but it can be absent in chronic osteomyelitis.16,17 There is some evidence that thrombocytosis may positively predict osteomyelitis in patients with chronic leg ulcers.18 If inflammatory markers are elevated, they can be trended for clinical correlation.19,20 Positive blood cultures in association with radiographic evidence of osteomyelitis may prevent the need for a more invasive bone biopsy.21

IMAGING

Plain film radiography is the first-line evaluation of suspected osteomyelitis. Advanced imaging is often needed for diagnosis following plain film radiography, because 50% to 75% of the bone matrix must be destroyed before lytic changes are evident on plain radiographs.22 Findings can include soft tissue swelling, osteopenia, cortical loss, bony destruction, and periosteal reaction12,23,24 (Figure 12 ). Advanced imaging can be guided by onset of symptoms and patient variables (Table 22,9,13,2430 ). Magnetic resonance imaging (MRI) has a high sensitivity and negative predictive value. Plain radiography and MRI are often both indicated and complementary13 (Figure 2, Figure 3, and Figure 4). Although contrast media is not required for diagnosis, it may be helpful to distinguish between abscess and phlegmon, especially in patients with chronic osteomyelitis.2527

FIGURE 1.

Plain film radiograph showing osteomyelitis of the distal fourth metatarsal and distal third and fourth phalanges (arrows). Cortical disruption and osteolysis are present.

Reprinted with permission from Hatzenbuehler J, Pulling TJ. Diagnosis and management of osteomyelitis. Am Fam Physician. 2011;84(9):1030.

TABLE 2. Diagnostic Imaging Studies and Osteomyelitis

Imaging modalitySensitivity (%)Specificity (%)Comments
Plain film radiography (anteroposterior, lateral, and oblique views)14 to 5468 to 70Preferred initial imaging modality; useful to rule out other bony pathology
MRI78 to 9060 to 90Intravenous contrast media preferred; useful to distinguish between soft tissue and bone infection, and to determine extent of infection; less useful in areas with surgical hardware because of image distortion
Computed tomography6750Contrast media preferred to help with soft tissue evaluation; may be used if MRI is contraindicated
UltrasonographyNANACannot be used to evaluate bone, but may be useful for identifying surrounding soft tissue changes or guiding needle aspiration; use for evaluation of suspected foreign body with negative results on radiography; may be used if MRI is contraindicated
Technetium-99 bone scintigraphy8225Low specificity, especially if patient has had recent trauma or surgery; useful to differentiate osteomyelitis from cellulitis; SPECT improves sensitivity; may be used if MRI is contraindicated
Leukocyte scintigraphy61 to 8460 to 68Combining with technetium-99 bone scintigraphy can increase specificity; may be used if MRI is contraindicated
Positron emission tomography9691Expensive; limited availability; may be used if MRI is contraindicated

MRI = magnetic resonance imaging; NA = not applicable; SPECT = single-photon emission computed tomography.

Adapted with permission from Hatzenbuehler J, Pulling TJ. Diagnosis and management of osteomyelitis. Am Fam Physician. 2011;84(9):1028, with additional information from references 9, 13, and 2430.

FIGURE 2.

Anteroposterior foot radiograph demonstrating focal osteopenia and cortical disruption of the third distal phalanx with surrounding periosteal reaction (short thick arrow), consistent with osteomyelitis. The first digit has been amputated at the level of the proximal phalanx diaphysis (long thin arrow) from prior osteomyelitis.

Copyright © Timothy G. Russell, MD

FIGURE 3.

Lateral foot radiograph demonstrating focal osteopenia and cortical disruption of the third distal phalanx with surrounding periosteal reaction (short thick arrow), consistent with osteomyelitis. A subtle lucency involving the soft tissues of the third distal phalanx tip (long thin arrow) is consistent with a superficial ulcer that was noted on physical examination.

Copyright © Timothy G. Russell, MD

FIGURE 4.

Axial T1-weighted (T1W) foot magnetic resonance imaging scan demonstrating confluent low T1 signal (compared to normal bone marrow) throughout the third distal phalanx marrow (short thick arrow), consistent with osteomyelitis. There is also some involvement of the head of the third middle phalanx (long thin arrow). The first digit has been amputated at the level of the proximal phalanx diaphysis (long thick arrow) from prior osteomyelitis.

Copyright © Timothy G. Russell, MD

MRI is more readily available and avoids radiation exposure, but positron emission tomography (PET) and single-photon emission computed tomography (SPECT) can also reliably diagnose osteomyelitis.25 In patients in whom MRI is contraindicated, a tagged leukocyte scan, computed tomography (CT), PET/CT, or sulfur colloid marrow scan can be appropriate; however, diagnosis may be impeded because of false-positive results from recent surgery or trauma, healed osteomyelitis, arthritis, bony tumors, Paget disease of bone, or reduced uptake secondary to necrosis and poor blood flow.13,29,30 Ultrasonography plays a complementary role to other modalities and may demonstrate inflammatory changes in the periosteum, particularly in children. Ultrasonography can be useful for identification of soft tissue abscess and helpful for abscess aspiration.13

Treatment

Osteomyelitis treatment requires a multifaceted approach that may include antibiotics, surgical intervention, and other modalities depending on multiple clinical factors, including clinical stage. Clinical staging guides decision-making when choosing specific surgical treatments and limits the need for amputation.31 The 2015 modification of the Cierny-Mader staging system (developed in 1985) is commonly used and classifies osteomyelitis based on the anatomic location and the physiologic condition of the patient.31,32 Anatomic types include medullary (stage 1), superficial (stage 2), localized (stage 3), and diffuse (stage 4), with higher stages requiring more complex surgical intervention.32 The physiologic condition of the patient (host) can be classified as type A (normal immune response and healthy vascular system), type B (local immunocompromise), or type C (noncandidate for surgery). In those classified as type C, treatment is expected to cause more harm than the disease process itself, so the focus of care shifts from cure to palliation.

ANTIBIOTICS

The choice of antibiotic therapy is specific to the culture results listed in Table 3.2,3337 It should be tailored to the individual patient based on susceptibility. Specific antibiotic coverage is usually indicated. In hospitalized patients at risk of methicillin-resistant S. aureus, empiric antibiotic coverage is recommended. Delaying antibiotic therapy until cultures are available is recommended except in patients in whom urgent intervention is necessary, such as those with severe sepsis, epidural extension, or neurologic involvement. The addition of rifampin to other antibiotics may also improve cure rates, especially when prosthetic joint or spinal implant infections are present.35,36 For adult patients hospitalized with osteomyelitis, parenteral followed by oral antibiotic therapy appears to be as effective as long-term parenteral therapy. Evidence suggests that oral antibiotics have similar cure rates and lower risks and costs compared with parenteral antibiotics.20,37,38 Treatment typically lasts four to six weeks, but comparisons of treatment duration have not been well studied.37

TABLE 3. Initial Antibiotic Therapy for Osteomyelitis in Adults

OrganismPreferred regimensAlternative regimens*
AnaerobesClindamycin, 600 mg IV every 6 hours
Ticarcillin/clavulanate (Timentin), 3.1 g IV every 4 hours
Cefotetan (Cefotan), 2 g IV every 12 hours
Metronidazole (Flagyl), 500 mg IV every 6 hours
Cutibacterium acnes (formerly known as Propionibacterium acnes)Penicillin G, 2 to 4 million units IV every 4 hoursCeftriaxone, 2 g IV every 24 hours
Enterobacteriaceae (e.g., Escherichia coli), quinolone resistantTicarcillin/clavulanate, 3.1 g IV every 4 hours
Piperacillin/tazobactam (Zosyn), 3.375 g IV every 6 hours
Ceftriaxone (Rocephin), 2 g IV every 24 hours
Enterobacteriaceae, quinolone sensitiveFluoroquinolone (e.g., ciprofloxacin, 400 mg IV every 8 to 12 hours)Ceftriaxone, 2 g IV every 24 hours
Ciprofloxacin, 750 mg orally every 12 hours
Levofloxacin (Levaquin), 750 mg orally every 24 hours
Pseudomonas aeruginosaCefepime, 2 g IV every 8 to 12 hours, plus ciprofloxacin, 400 mg IV every 8 to 12 hoursImipenem/cilastatin (Primaxin), 1 g IV every 8 hours, plus aminoglycoside
Piperacillin/tazobactam, 3.375 g IV every 6 hours, plus ciprofloxacin, 400 mg IV every 12 hours
Staphylococcus aureus, methicillin resistantVancomycin, 15 to 20 mg per kg per dose IV every 8 to 12 hours
For patients allergic to vancomycin:
Linezolid (Zyvox), 600 mg IV every 12 hours
or
Rifampin, 600 mg daily
Daptomycin (Cubicin), 6 mg per kg IV every 24 hours
Linezolid, 600 mg IV or orally every 12 hours
Clindamycin, 600 mg IV or orally every 8 hours
Trimethoprim/sulfamethoxazole, 3.5 to 4.0 mg per kg per dose or 2 double-strength tablets (for an 80-kg [176-lb] adult) IV or orally every 8 to 12 hours
S. aureus, methicillin sensitiveNafcillin or oxacillin, 1 to 2 g IV every 4 hours
Cefazolin, 1 to 1.5 g IV every 6 hours
Ceftriaxone, 2 g IV every 24 hours
Vancomycin, 1 g IV every 12 hours
Streptococcus speciesPenicillin G, 2 to 4 million units IV every 4 hoursCeftriaxone, 2 g IV every 24 hours
Clindamycin, 600 mg IV every 6 hours

IV = intravenously.

*—Alternative regimens are available if the patient has an allergy to the preferred regimen, does not have access to the preferred regimen, or does not tolerate the preferred regimen because of other medical complications (e.g., chronic kidney disease, liver failure, drug interactions).

Adapted with permission from Hatzenbuehler J, Pulling TJ. Diagnosis and management of osteomyelitis. Am Fam Physician. 2011;84(9):1031, with additional information from references 3337.

DEBRIDEMENT

Surgical bony debridement followed by drainage of any associated soft tissue abscess continues to be a mainstay of therapy, although there is no clear recommendation about which cases will require debridement.36 Debridement is typically indicated as part of the initial treatment in the presence of underlying orthopedic hardware and necrotic bone. Stabilization of the bone is an essential component of debridement and can decrease healing time and complications. Surgical debridement after antibiotic therapy shortens hospital stays, reduces medical costs, provides satisfactory infection control, and prevents complications of long-term systemic antibiotic use.39 Debridement can be supplemented with the placement of antibiotic-loaded collagen sponges, which has some evidence supporting improved outcomes.40 Hyperbaric oxygen therapy can be used as an adjunctive modality and may be particularly helpful in cases of chronic osteomyelitis.41

Special Considerations

When selecting treatment strategies for osteomyelitis, several groups of patients require special considerations, such as children and patients who have prosthetic joints, vertebral osteomyelitis, and diabetes. The treatment of these groups is beyond the scope of this article.

This article updates a previous article on this topic by Hatzenbuehler, et al.2

Data Sources: A PubMed search was completed in Clinical Queries using the key terms osteomyelitis, imaging, diagnosis, and treatment. The search included meta-analyses, randomized controlled trials, clinical trials, and reviews. Also searched were the Cochrane database, the Database of Abstracts of Reviews of Effectiveness (DARE), Dynamed, and Essential Evidence Plus. Search dates: August 11, 2020, and March 10, 2021.

Figure 2Figure 3, and Figure 4 provided by Timothy G. Russell, MD, Department of Radiology, Martin Army Community Hospital.

The opinions and assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of the U.S. Army Medical Department or the U.S. Army at large.

DAVID C. BURY, DO, MPH, FAAFP, is program director of the Family Medicine Residency Program at Martin Army Community Hospital, Fort Benning, Ga., and is assistant professor in the Department of Family Medicine at the Uniformed Services University of the Health Sciences, Bethesda, Md. At the time this article was written, Dr. Bury was a fellow in the Leadership and Faculty Development Fellowship Program at Madigan Army Medical Center, Joint Base Lewis-McChord, Wash.

TYLER S. ROGERS, MD, FAAFP, is a fellow in the Leadership and Faculty Development Fellowship Program at Madigan Army Medical Center, an assistant professor in the Department of Family Medicine at the Uniformed Services University of the Health Sciences, and a clinical assistant professor in the Department of Family Medicine at the University of Washington School of Medicine, Seattle.

MICHAEL M. DICKMAN, DO, MBA, FAAFP, is Chief of the Department of Soldier and Community Health at Madigan Army Medical Center, an assistant professor in the Department of Family Medicine at the Uniformed Services University of the Health Sciences, and a clinical assistant professor in the Department of Family Medicine at the University of Washington School of Medicine. At the time this article was written, Dr. Dickman was a fellow in the Leadership and Faculty Development Fellowship Program at Madigan Army Medical Center.

Address correspondence to David C. Bury, DO, MPH, FAAFP, 6600 Van Aalst Blvd., Fort Benning, GA 31905 (email: david.c.bury@gmail.com). Reprints are not available from the authors.

Author disclosure: No relevant financial affiliations.

  1. 1.Lew DP, Waldvogel FA. Osteomyelitis. Lancet. 2004;364(9431):369-379.
  2. 2.Hatzenbuehler J, Pulling TJ. Diagnosis and management of osteomyelitis. Am Fam Physician. 2011;84(9):1027-1033. Accessed January 29, 2021. https://www.aafp.org/afp/2011/1101/p1027.html
  3. 3.Waldvogel FA, Medoff G, Swartz MN. Osteomyelitis: a review of clinical features, therapeutic considerations and unusual aspects. N Engl J Med. 1970;282(4):198-206.
  4. 4.Holzman RS, Bishko F. Osteomyelitis in heroin addicts. Ann Intern Med. 1971;75(5):693-696.
  5. 5.Aragón-Sánchez J, Lázaro-Martínez JL, Quintana-Marrero Y, et al.; Are diabetic foot ulcers complicated by MRSA osteomyelitis associated with worse prognosis? Outcomes of a surgical series. Diabet Med. 2009;26(5):552-555.
  6. 6.Kohli R, Hadley S. Fungal arthritis and osteomyelitis. Infect Dis Clin North Am. 2005;19(4):831-851.
  7. 7.Truntzer J, Vopat B, Feldstein M, et al. Smoking cessation and bone healing: optimal cessation timing. Eur J Orthop Surg Traumatol. 2015;25(2):211-215.
  8. 8.Newman LG, Waller J, Palestro CJ, et al. Unsuspected osteomyelitis in diabetic foot ulcers. Diagnosis and monitoring by leukocyte scanning with indium in 111 oxyquinoline. JAMA. 1991;266(9):1246-1251.
  9. 9.Fritz JM, McDonald JR. Osteomyelitis: approach to diagnosis and treatment. Phys Sportsmed. 2008;36(1):nihpa116823.
  10. 10.Lam K, van Asten SAV, Nguyen T, et al. Diagnostic accuracy of probe to bone to detect osteomyelitis in the diabetic foot: a systematic review. Clin Infect Dis. 2016;63(7):944-948.
  11. 11.Senneville É, Lipsky BA, Abbas ZG, et al. Diagnosis of infection in the foot in diabetes: a systematic review. Diabetes Metab Res Rev. 2020;36(suppl 1):e3281.
  12. 12.Lipsky BA, Berendt AR, Deery HG, et al.; Infectious Diseases Society of America. Diagnosis and treatment of diabetic foot infections. Plast Reconstr Surg. 2006;117(7 suppl):212S-238S.
  13. 13.Beaman FD, von Herrmann PF, Kransdorf MJ, et al.; Expert Panel on Musculoskeletal Imaging. ACR Appropriateness Criteria Suspected osteomyelitis, septic arthritis, or soft tissue infection (excluding spine and diabetic foot). J Am Coll Radiol. 2017;14(5S):S326-S337.
  14. 14.O'Rourke S, Meehan M, Bennett D, et al. The role of real-time PCR testing in the investigation of paediatric patients with community-onset osteomyelitis and septic arthritis. Ir J Med Sci. 2019;188(4):1289-1295.
  15. 15.Mikus JR, Worsham J, Aung H, et al. The role of bone biopsy in osteomyelitis—utility or futility? J Vasc Interv Radiol. 2013;24(4):S31-S32
  16. 16.Perry M. Erythrocyte sedimentation rate and C reactive protein in the assessment of suspected bone infection—are they reliable indices? J R Coll Surg Edinb. 1996;41(2):116-118.
  17. 17.Unkila-Kallio L, Kallio MJ, Eskola J, et al. Serum C-reactive protein, erythrocyte sedimentation rate, and white blood cell count in acute hematogenous osteomyelitis of children. Pediatrics. 1994;93(1):59-62.
  18. 18.Schattner A, Dubin I, Gelber M. A new diagnostic clue to osteomyelitis in chronic leg ulcers. Am J Med. 2016;129(5):538-539.
  19. 19.Saavedra-Lozano J, Mejías A, Ahmad N, et al. Changing trends in acute osteomyelitis in children: impact of methicillin-resistant Staphylococcus aureus infections. J Pediatr Orthop. 2008;28(5):569-575.
  20. 20.Spellberg B, Lipsky BA. Systemic antibiotic therapy for chronic osteomyelitis in adults. Clin Infect Dis. 2012;54(3):393-407.
  21. 21.Calhoun JH, Manring MM. Adult osteomyelitis. Infect Dis Clin North Am. 2005;19(4):765-786.
  22. 22.Butt WP. The radiology of infection. Clin Orthop Relat Res. 1973;(96):20-30.
  23. 23.Darouiche RO, Landon GC, Klima M, et al. Osteomyelitis associated with pressure sores. Arch Intern Med. 1994;154(7):753-758.
  24. 24.Gold RH, Hawkins RA, Katz RD. Bacterial osteomyelitis: findings on plain radiography, CT, MR, and scintigraphy. AJR Am J Roentgenol. 1991;157(2):365-370.
  25. 25.Llewellyn A, Jones-Diette J, Kraft J, et al. Imaging tests for the detection of osteomyelitis: a systematic review. Health Technol Assess. 2019;23(61):1-128.
  26. 26.Erdman WA, Tamburro F, Jayson HT, et al. Osteomyelitis: characteristics and pitfalls of diagnosis with MR imaging. Radiology. 1991;180(2):533-539.
  27. 27.Durham JR, Lukens ML, Campanini DS, et al. Impact of magnetic resonance imaging on the management of diabetic foot infections. Am J Surg. 1991;162(2):150-153.
  28. 28.Pineda C, Vargas A, Rodríguez AV. Imaging of osteomyelitis: current concepts. Infect Dis Clin North Am. 2006;20(4):789-825.
  29. 29.Lauri C, Tamminga M, Glaudemans AWJM, et al. Detection of osteomyelitis in the diabetic foot by imaging techniques: a systematic review and meta-analysis comparing MRI, white blood cell scintigraphy, and FDG-PET. Diabetes Care. 2017;40(8):1111-1120.
  30. 30.Demirev A, Weijers R, Geurts J, et al. Comparison of [18 F] FDG PET/CT and MRI in the diagnosis of active osteomyelitis. Skeletal Radiol. 2014;43(5):665-672.
  31. 31.Marais LC, Ferreira N, Aldous C, et al. A modified staging system for chronic osteomyelitis. J Orthop. 2015;12(4):184-192.
  32. 32.Cierny G. Surgical treatment of osteomyelitis. Plast Reconstr Surg. 2011;127(suppl 1):190S-204S.
  33. 33.Roblot F, Besnier JM, Juhel L, et al. Optimal duration of antibiotic therapy in vertebral osteomyelitis. Semin Arthritis Rheum. 2007;36(5):269-277.
  34. 34.Karamanis EM, Matthaiou DK, Moraitis LI, et al. Fluoroquinolones versus beta-lactam based regimens for the treatment of osteomyelitis: a meta-analysis of randomized controlled trials. Spine (Phila Pa 1976). 2008;33(10):E297-E304.
  35. 35.Davis JS. Management of bone and joint infections due to Staphylococcus aureus. Intern Med J. 2005;35(suppl 2):S79-S96.
  36. 36.Liu C, Bayer A, Cosgrove SE, et al.; Infectious Diseases Society of America. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children [published correction appears in Clin Infect Dis. 2011;53(3):319]. Clin Infect Dis. 2011;52(3):e18-e55.
  37. 37.Conterno LO, Turchi MD. Antibiotics for treating chronic osteomyelitis in adults. Cochrane Database Syst Rev. 2013;(9):CD004439.
  38. 38.Li HK, Rombach I, Zambellas R, et al.; OVIVA Trial Collaborators. Oral versus intravenous antibiotics for bone and joint infection. N Engl J Med. 2019;380(5):425-436.
  39. 39.Shih HN, Shih LY, Wong YC. Diagnosis and treatment of subacute osteomyelitis. J Trauma. 2005;58(1):83-87.
  40. 40.van Vugt TAG, Walraven JMB, Geurts JAP, et al. Antibiotic-loaded collagen sponges in clinical treatment of chronic osteomyelitis: a systematic review. J Bone Joint Surg Am. 2018;100(24):2153-2161.
  41. 41.Savvidou OD, Kaspiris A, Bolia IK, et al. Effectiveness of hyperbaric oxygen therapy for the management of chronic osteomyelitis: a systematic review of the literature. Orthopedics. 2018;41(4):193-199.

Copyright © 2026 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. See permissions for copyright questions and/or permission requests.